Cangrelor

  • Check with publisher
  • Published date: July 20, 2020
    • Shirley, New York, United States

Cangrelor, an adenylic acid derivative, has been found to be a P2Y12 inhibitor that could be effective in some coronary artery diseases. It is approved by FDA as an antiplatelet drug. It has been used to reduce the risk of heart attack during cardiology procedures. https://www.bocsci.com/cangrelor-cas-163706-06-7-item-423545.html

Result 0 votes
Alex Brown
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Pentagastrin

    Pentagastrin

    Drug Development Shirley (New York) July 20, 2020 Check with publisher

    A synthetic pentapeptide that mimics endogenous gastrin when given parenterally. It functions via stimulating the secretion of gastric acid, pepsin, and intrinsic factor. https://www.bocsci.com/pentagastrin-cas-5534-95-2-item-71440.html

  • PCI-27483

    PCI-27483

    Drug Development Shirley (New York) July 20, 2020 Check with publisher

    PCI-27483 is a reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities. FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex...

  • Rupintrivir

    Rupintrivir

    Drug Development Shirley (New York) July 20, 2020 Check with publisher

    Rupintrivir is a potent and selective irreversible human rhinovirus (HRV) 3C protease inhibitor (EC50 = 5 nM). It has been demonstrated to have in vitro activity against all HRVs tested, consistent with its interaction with a strictly conserved subse...